218 related articles for article (PubMed ID: 20423225)
1. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies.
Garcia-Fabiani MB; Haase S; Comba A; Carney S; McClellan B; Banerjee K; Alghamri MS; Syed F; Kadiyala P; Nunez FJ; Candolfi M; Asad A; Gonzalez N; Aikins ME; Schwendeman A; Moon JJ; Lowenstein PR; Castro MG
Front Oncol; 2021; 11():631037. PubMed ID: 34168976
[TBL] [Abstract][Full Text] [Related]
2. A pretargeting nanoplatform for imaging and enhancing anti-inflammatory drug delivery.
Khang MK; Zhou J; Co CM; Li S; Tang L
Bioact Mater; 2020 Dec; 5(4):1102-1112. PubMed ID: 32695939
[TBL] [Abstract][Full Text] [Related]
3. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer.
Wei W; Liu Q; Jiang D; Zhao H; Kutyreff CJ; Engle JW; Liu J; Cai W
Adv Sci (Weinh); 2020 Jul; 7(13):1903595. PubMed ID: 32670751
[TBL] [Abstract][Full Text] [Related]
4. Engineering Polymer-Binding Bispecific Antibodies for Enhanced Pretargeted Delivery of Nanoparticles to Mucus-Covered Epithelium.
Huckaby JT; Parker CL; Jacobs TM; Schaefer A; Wadsworth D; Nguyen A; Wang A; Newby J; Lai SK
Angew Chem Int Ed Engl; 2019 Apr; 58(17):5604-5608. PubMed ID: 30811861
[TBL] [Abstract][Full Text] [Related]
5. Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.
Colby AH; Liu R; Schulz MD; Padera RF; Colson YL; Grinstaff MW
Sci Rep; 2016 Jan; 6():18720. PubMed ID: 26740245
[TBL] [Abstract][Full Text] [Related]
6. Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.
Yang Q; Parker CL; McCallen JD; Lai SK
J Control Release; 2015 Dec; 220(Pt B):715-26. PubMed ID: 26407672
[TBL] [Abstract][Full Text] [Related]
7. Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.
Li L; Zhang CL; Kang L; Wang RF; Yan P; Zhao Q; Yin L; Guo FQ
Cancer Biother Radiopharm; 2015 Oct; 30(8):342-8. PubMed ID: 26382009
[TBL] [Abstract][Full Text] [Related]
8. Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.
Ménager J; Gorin JB; Maurel C; Drujont L; Gouard S; Louvet C; Chérel M; Faivre-Chauvet A; Morgenstern A; Bruchertseifer F; Davodeau F; Gaschet J; Guilloux Y
PLoS One; 2015; 10(6):e0130249. PubMed ID: 26098691
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of human tumours.
Larson SM; Carrasquillo JA; Cheung NK; Press OW
Nat Rev Cancer; 2015 Jun; 15(6):347-60. PubMed ID: 25998714
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
11. Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas.
Cairo MS; Woessmann W; Pagel J
Biol Blood Marrow Transplant; 2013 Jan; 19(1 Suppl):S38-43. PubMed ID: 23073268
[No Abstract] [Full Text] [Related]
12. Radiation-induced tumor neoantigens: imaging and therapeutic implications.
Corso CD; Ali AN; Diaz R
Am J Cancer Res; 2011; 1(3):390-412. PubMed ID: 21969260
[TBL] [Abstract][Full Text] [Related]
13. Chemically modified antibodies as diagnostic imaging agents.
Day JJ; Marquez BV; Beck HE; Aweda TA; Gawande PD; Meares CF
Curr Opin Chem Biol; 2010 Dec; 14(6):803-9. PubMed ID: 20952245
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy for hematologic and other malignancies.
Walter RB; Press OW; Pagel JM
Cancer Biother Radiopharm; 2010 Apr; 25(2):125-42. PubMed ID: 20423225
[TBL] [Abstract][Full Text] [Related]
15. Leveraging Bioorthogonal Click Chemistry to Improve
Poty S; Carter LM; Mandleywala K; Membreno R; Abdel-Atti D; Ragupathi A; Scholz WW; Zeglis BM; Lewis JS
Clin Cancer Res; 2019 Jan; 25(2):868-880. PubMed ID: 30352909
[TBL] [Abstract][Full Text] [Related]
16. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
Weiden PL; Breitz HB
Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
[TBL] [Abstract][Full Text] [Related]
17. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Applications of Pretargeting.
Verhoeven M; Seimbille Y; Dalm SU
Pharmaceutics; 2019 Sep; 11(9):. PubMed ID: 31480515
[TBL] [Abstract][Full Text] [Related]
19. Status of radioimmunotherapy in the new millennium.
Imam SK
Cancer Biother Radiopharm; 2001 Jun; 16(3):237-56. PubMed ID: 11471488
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
